Biomarin Pharma Earnings, Revenue beat in Q1 By Investing.com

Biomarin Pharma (NASDAQ:BMRN) reported on Thursday first quarter earnings that beat analysts’ forecasts and revenue that topped expectations.

Biomarin Pharma announced earnings per share of $0.09 on revenue of $486M. Analysts polled by Investing.com anticipated EPS of $-0.0923 on revenue of $446.78M.

Biomarin Pharma shares are down 8.5% from the beginning of the year and are trading at $80.24 , down-from-52-week-high.They are under-performing the Nasdaq which is up 9.27% from the start of the year.

Biomarin Pharma follows other major Healthcare sector earnings this month

Biomarin Pharma’s report follows an earnings beat by J&J on April 20, who reported EPS of $2.59 on revenue of $22.32B, compared to forecasts EPS of $2.34 on revenue of $21.98B.

Abbott Labs had beat expectations on April 20 with first quarter EPS of $1.32 on revenue of $10.46B, compared to forecast for EPS of $1.27 on revenue of $10.69B.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar